{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:24:24Z","timestamp":1794407064405,"version":"4.9.0"},"reference-count":45,"publisher":"American Academy of Pediatrics (AAP)","issue":"Supplement_2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"abstract":"<jats:p>Duchenne muscular dystrophy is associated with an increased risk of bone fragility due to the adverse effects of prolonged glucocorticoid therapy and progressive muscle weakness on bone strength. Osteoporosis manifests clinically as low-trauma long-bone and vertebral fractures (VFs), with VFs frequent, particularly in those treated with glucocorticoid therapy. It is increasingly recognized that bone pain, medical complications of osteoporosis (such as fat embolism syndrome), and the potential for permanent, fracture-induced loss of ambulation can be mitigated with timely bone health surveillance and management. This includes periodic spine radiographs for VF detection because VFs can be asymptomatic in their early phases and thereby go undetected in the absence of monitoring. With this article, we provide a comprehensive review of the following 4 phases of bone health management: (1) bone health monitoring, which is used to identify early signs of compromised bone health; (2) osteoporosis stabilization, which is aimed to mitigate back pain and interrupt the fracture\u2013refracture cycle through bone-targeted therapy; (3) bone health maintenance, which has the goal to preserve the clinical gains realized during the stabilization phase through ongoing bone-targeted therapy; and (4) osteoporosis therapy discontinuation, which places those who are eligible for discontinuation of osteoporosis treatment back on a health monitoring program. In the course of reviewing these 4 phases of management, we will discuss the criteria for diagnosing osteoporosis, along with detailed recommendations for osteoporosis intervention including specific drugs, dose, length of therapy, contraindications, and monitoring of treatment efficacy and safety.<\/jats:p>","DOI":"10.1542\/peds.2018-0333e","type":"journal-article","created":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T04:26:19Z","timestamp":1538367979000},"page":"S34-S42","source":"Crossref","is-referenced-by-count":91,"title":["Bone Health and Osteoporosis Management of the Patient With Duchenne Muscular Dystrophy"],"prefix":"10.1542","volume":"142","author":[{"given":"Leanne M.","family":"Ward","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stasia","family":"Hadjiyannakis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh J.","family":"McMillan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garey","family":"Noritz","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital, The Ohio State University, Columbus, Ohio; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Weber","sequence":"additional","affiliation":[{"name":"Golisano Children\u2019s Hospital, School of Medicine and Dentistry, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2018,10,1]]},"reference":[{"issue":"2","key":"2021120817531762500_B1","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00198-016-3774-5","article-title":"The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.","volume":"28","author":"Ma","year":"2017","journal-title":"Osteoporos Int"},{"issue":"12","key":"2021120817531762500_B2","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.nmd.2012.07.010","article-title":"Fat Embolism Syndrome following minor trauma in Duchenne muscular dystrophy.","volume":"22","author":"McAdam","year":"2012","journal-title":"Neuromuscul Disord"},{"issue":"14","key":"2021120817531762500_B3","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/WNL.0b013e31828ab313","article-title":"Fat embolism syndrome in patients with Duchenne muscular dystrophy.","volume":"80","author":"Medeiros","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"2021120817531762500_B4","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2010-1666","article-title":"Impact of bisphosphonates on survival for patients with Duchenne muscular dystrophy.","volume":"127","author":"Gordon","year":"2011","journal-title":"Pediatrics"},{"issue":"1","key":"2021120817531762500_B5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/01241398-200001000-00016","article-title":"Bone mineral density and fractures in boys with Duchenne muscular dystrophy.","volume":"20","author":"Larson","year":"2000","journal-title":"J Pediatr Orthop"},{"issue":"10","key":"2021120817531762500_B6","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1469-8749.2002.tb00272.x","article-title":"Fracture prevalence in Duchenne muscular dystrophy.","volume":"44","author":"McDonald","year":"2002","journal-title":"Dev Med Child Neurol"},{"issue":"19","key":"2021120817531762500_B7","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1212\/01.wnl.0000260974.41514.83","article-title":"Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.","volume":"68","author":"King","year":"2007","journal-title":"Neurology"},{"issue":"11","key":"2021120817531762500_B8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.nmd.2016.08.011","article-title":"Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.","volume":"26","author":"Tian","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"2021120817531762500_B9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"2","key":"2021120817531762500_B10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jocd.2014.01.003","article-title":"Dual-energy x-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD Pediatric Official Positions.","volume":"17","author":"Crabtree","year":"2014","journal-title":"J Clin Densitom"},{"issue":"3","key":"2021120817531762500_B11","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1359\/jbmr.091007","article-title":"The relationship between fractures and DXA measures of BMD in the distal femur of children and adolescents with cerebral palsy or muscular dystrophy.","volume":"25","author":"Henderson","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2021120817531762500_B12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jocd.2009.01.005","article-title":"Revised pediatric reference data for the lateral distal femur measured by Hologic Discovery\/Delphi dual-energy x-ray absorptiometry.","volume":"12","author":"Zemel","year":"2009","journal-title":"J Clin Densitom"},{"key":"2021120817531762500_B13","volume-title":"Radiographic Atlas of Skeletal Development of the Hand and Wrist","author":"Greulich","year":"1959","edition":"2nd ed."},{"issue":"1","key":"2021120817531762500_B14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0169-6009(92)90712-M","article-title":"Bone densitometry of the spine and femur in children by dual-energy x-ray absorptiometry.","volume":"17","author":"Kr\u00f6ger","year":"1992","journal-title":"Bone Miner"},{"issue":"10","key":"2021120817531762500_B15","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1210\/jc.2011-1111","article-title":"Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study.","volume":"96","author":"Zemel","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2021120817531762500_B16","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/jbmr.2511","article-title":"Incident Vertebral Fractures and Risk Factors in the First Three Years Following Glucocorticoid Initiation Among Pediatric Patients With Rheumatic Disorders","volume":"30","author":"LeBlanc","year":"2015","journal-title":"J Bone Miner Res"},{"key":"2021120817531762500_B17","volume-title":"Dietary Reference Intakes for Calcium and Vitamin D","author":"Institute of Medicine","year":"2011"},{"issue":"7","key":"2021120817531762500_B18","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.","volume":"96","author":"Holick","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2021120817531762500_B19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1210\/jc.2007-2308","article-title":"Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D.","volume":"93","author":"Holick","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2021120817531762500_B20","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1210\/jc.2004-0360","article-title":"Vitamin D2 is much less effective than vitamin D3 in humans.","volume":"89","author":"Armas","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2021120817531762500_B21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0304-3959(01)00314-1","article-title":"The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement.","volume":"93","author":"Hicks","year":"2001","journal-title":"Pain"},{"issue":"9","key":"2021120817531762500_B22","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique.","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2021120817531762500_B23","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1359\/jbmr.090202","article-title":"Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program.","volume":"24","author":"Halton","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2021120817531762500_B24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00247-014-3210-y","article-title":"Common normal variants of pediatric vertebral development that mimic fractures: a pictorial review from a national longitudinal bone health study.","volume":"45","author":"Jaremko","year":"2015","journal-title":"Pediatr Radiol"},{"issue":"7","key":"2021120817531762500_B25","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00198-016-3515-9","article-title":"The management of osteoporosis in children.","volume":"27","author":"Ward","year":"2016","journal-title":"Osteoporos Int"},{"issue":"6","key":"2021120817531762500_B26","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/MED.0000000000000106","article-title":"Diagnosis and treatment of pediatric osteoporosis.","volume":"21","author":"Bachrach","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"5","key":"2021120817531762500_B27","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.","volume":"20","author":"Gatti","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2021120817531762500_B28","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpeds.2006.03.013","article-title":"Early bisphosphonate treatment in infants with severe osteogenesis imperfecta.","volume":"149","author":"Antoniazzi","year":"2006","journal-title":"J Pediatr"},{"issue":"4","key":"2021120817531762500_B29","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/adc.2006.096552","article-title":"Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.","volume":"92","author":"Astr\u00f6m","year":"2007","journal-title":"Arch Dis Child"},{"key":"2021120817531762500_B30","first-page":"0","article-title":"A randomized, placebo-controlled trial of oral alendronate in children and adolescents with osteogenesis imperfecta.","volume":"36","author":"Ward","year":"2005","journal-title":"Bone"},{"issue":"7","key":"2021120817531762500_B31","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1359\/jbmr.090213","article-title":"Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.","volume":"24","author":"Rauch","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"9419","key":"2021120817531762500_B32","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study.","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet"},{"issue":"7","key":"2021120817531762500_B33","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1210\/jc.2004-2054","article-title":"Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I.","volume":"90","author":"Ward","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"9902","key":"2021120817531762500_B34","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(13)61531-7","article-title":"Oral bisphosphonates for paediatric osteogenesis imperfecta?","volume":"382","author":"Ward","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"2021120817531762500_B35","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000323368","article-title":"Zoledronic acid treatment in children with osteogenesis imperfecta.","volume":"75","author":"Vuorimies","year":"2011","journal-title":"Horm Res Paediatr"},{"issue":"14","key":"2021120817531762500_B36","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"2021120817531762500_B37","first-page":"e20180333F","article-title":"Obesity and endocrine management of the patient with Duchenne muscular dystrophy.","volume":"142","author":"Weber","year":"2018","journal-title":"Pediatrics"},{"issue":"8","key":"2021120817531762500_B38","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrrheum.2013.45","article-title":"Causes, mechanisms and management of paediatric osteoporosis.","volume":"9","author":"M\u00e4kitie","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"2021120817531762500_B39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000369582","article-title":"The long-term effects of switching from active intravenous bisphosphonate treatment to low-dose maintenance therapy in children with osteogenesis imperfecta.","volume":"83","author":"Biggin","year":"2015","journal-title":"Horm Res Paediatr"},{"issue":"4","key":"2021120817531762500_B40","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.bone.2006.11.020","article-title":"Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta.","volume":"40","author":"Rauch","year":"2007","journal-title":"Bone"},{"issue":"4","key":"2021120817531762500_B41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/07853890510007386","article-title":"Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?","volume":"37","author":"Rauch","year":"2005","journal-title":"Ann Med"},{"issue":"12","key":"2021120817531762500_B42","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/jbmr.2567","article-title":"Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years.","volume":"30","author":"Palomo","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2021120817531762500_B43","first-page":"324","article-title":"Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.","volume":"60","author":"Brown","year":"2014","journal-title":"Can Fam Physician"},{"key":"2021120817531762500_B44","doi-asserted-by":"crossref","first-page":"928385","DOI":"10.1155\/2015\/928385","article-title":"Optimizing bone health in Duchenne muscular dystrophy.","volume":"2015","author":"Buckner","year":"2015","journal-title":"Int J Endocrinol"},{"issue":"11","key":"2021120817531762500_B45","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s00198-012-1911-3","article-title":"The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.","volume":"23","author":"Sbrocchi","year":"2012","journal-title":"Osteoporos Int"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/142\/Supplement_2\/S34\/904863\/peds_20180333e.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/142\/Supplement_2\/S34\/904863\/peds_20180333e.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T14:18:50Z","timestamp":1638973130000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/142\/Supplement_2\/S34\/11551\/Bone-Health-and-Osteoporosis-Management-of-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":45,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2018,10,1]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2018-0333e","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}